このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

アルファ細胞からベータ細胞へのコミュニケーションによるインスリン抵抗性への適応とインスリン分泌の役割 (UPGRADE)

2026年9月28日 更新者:David D'Alessio, M.D.

健康と疾患におけるアルファ細胞からベータ細胞へのコミュニケーション

Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects. This protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.

調査の概要

詳細な説明

Subjects will undergo screening for medical history, medication usage, and blood work; those who qualify will be offered participation. Study participation will last approximately 4-8 weeks depending on the study protocol enrolled and appointment availability.

Aim 2A (Aim 1 of the protocol): Each participant will have two 5-hour hyperglycemic clamp procedures to test the effect of fasting glucagon-like peptide 1 (GLP-1) action before and after experimental insulin resistance. The effect of endogenous proglucagon peptides (glucagon and GLP-1) to stimulate insulin secretion will be determined by blockade of the GLP-1 receptor with the antagonist exendin-9 (Ex-9) during glucose infusions. Insulin secretion experiments will be repeated before and after induction of insulin resistance. To induce insulin resistance, subjects will take dexamethasone, a synthetic glucocorticoid that has been shown in published studies and in a pilot study by our group to reduce insulin sensitivity by ~30%.

Effective following a protocol revision in August 2026, participants in Aim 2A will also complete a third study visit that consists of two identical, sequential hyperglycemic clamps to evaluate time-of-day effects on insulin response independent of Ex-9. This protocol revision is a result of observations from the Aim 2A sub-study.

Aim 2A sub-study (Aim 1a of the protocol): Implemented in July 2026, a small subset of participants completed a single study visit to undergo two identical, sequential hyperglycemic clamps to examine potential time-of-day effects on glucose-stimulated insulin secretion.

Aim 2B (Aim 2 of the protocol): This study will recruit non-diabetic subjects with obesity. They will be studied on two occasions using a 4.5-hour procedure with a hyperglycemic clamp to measure insulin secretion, followed by a hyperinsulinemic, euglycemic clamp to measure insulin sensitivity. This procedure will be done 2 times, once with saline infused during hyperglycemia as a control, and once with exendin-9 given during hyperglycemia to determine the role of GLP-1 receptor action.

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • North Carolina
      • Durham、North Carolina、アメリカ、27705
        • 募集
        • Duke Center for Living
        • コンタクト:
        • 主任研究者:
          • David D'Alessio, MD
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~60年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Aim 2A and 2A sub-study: Inclusion Criteria:

  • Age 18-45
  • Body Mass Index (BMI) < 27.0
  • Fasting plasma glucose of ≤ 95 mg/dL or HbA1c value ≤ 5.8% as measured at screening visit

Exclusion Criteria:

  • Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
  • Personal history of diabetes or pancreatitis
  • Personal history of cardiac, gastrointestinal, renal or liver disease
  • Immediate family history of diabetes
  • Renal insufficiency (eGFR < 60 mL/kg/min)
  • Anemia (hematocrit < 34%) as measured at screening visit
  • Pregnant females
  • Poor vein access
  • Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)
  • Apparent sensitivity to the study peptide as determined by the skin test

Aim 2B: Inclusion Criteria:

  • Age 35-60
  • Body Mass Index (BMI) ≥ 27.0
  • Fasting plasma glucose of < 126 mg/dL or HbA1c value < 6.5% as measured at screening visit

Exclusion Criteria:

  • Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
  • Personal history of diabetes or pancreatitis
  • Personal history of cardiac, gastrointestinal, renal or liver disease
  • Immediate family history of diabetes
  • Renal insufficiency (eGFR < 60 mL/kg/min)
  • AST and/or ALT levels > 3x the upper limit of the normal range
  • Anemia (hematocrit < 34%) as measured at screening visit
  • Pregnant females
  • Poor vein access
  • Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)
  • Apparent sensitivity to the study peptide as determined by the skin test

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:2A [revised 8/2026]: Glucose-stimulated insulin secretion with and without GLP-1 receptor blockade

Aim 2A [revised AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive an infuson of saline during the first clamp and receive exendin-9 (600 pmol/kg/min) during the second clamp. Intervention: The interventions here are the experimental hyperglycemia with and without exendin-9.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Dexamethasone 6 mg daily; administered for 7 days leading up to the second exendin-9 experiment in Aim 2A

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

実験的:Aim 2A [revised 8/2026]: Sequential glucose-stimulated insulin secretion

Aim 2A [revised AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive an infusion of saline during both clamps and the procedure will align with the temporal pattern applied during all procedures in Aim 2A. Experiment: The experiment in this arm is the examination of potential time of day effects on glucose-stimulated insulin secretion.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

実験的:2A [discont'd 8/2026]: Glucose-stimulated insulin secretion with and without GLP-1 receptor blockade

Aim 2A [discontinued AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained stable at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive either saline or exendin-9 (600 pmol/kg/min) during the clamps; in 10 subjects the saline/clamp will be first and in 10 subjects the exendin-9/clamp will be first; this will be assigned in alternating order as individuals are enrolled. Intervention: The interventions here are the experimental hyperglycemia with and without exendin-9.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

実験的:2A: Glucose-stimulated insulin secretion with/without GLP-1 receptor blockade and insulin resistance

Aim 2A: Subjects will be treated with 6 mg dexamethasone once daily for 7 days to induce insulin resistance before repeating the 5 hr glucose clamp study. The infusion of glucose with saline and exendin-9 will be performed identically to the first study. Intervention: The intervention in this arm is the induction of insulin resistance with dexamethasone treatment.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

実験的:2B: Glucose-stimulated insulin secretion and insulin sensitivity

Aim 2B: Each subject will have a 4.5 hr experiment with a 90-minute hyperglycemic clamp at a level of 2.5 mM above fasting glucose followed by a 60-minute gradual reduction in glucose infusion that leads to a 90-minute hyperinsulinemic (80 units/meter2 Body Surface Area/minute), euglycemic clamp at a level of 6 mM.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

実験的:2B: Glucose-stimulated insulin secretion with GLP-1 receptor blockade and insulin sensitivity

Aim 2B: Subjects will receive an infusion of exendin-9 (600 pmol/kg/min) or saline during the 90-minute hyperglycemic clamp period of the procedure. Subjects receiving exendin-9 during their first procedure will receive saline during their second procedure and vice versa; in 10 subjects the saline/clamp will be administered first and in 10 subjects the exendin-9/clamp will be administered first; this will be assigned in alternating order as individuals are enrolled. The hyperinsulinemic, euglycemic clamp during the second portion of the procedure will be conducted identically to the control arm.

Intervention: The intervention in this study is the administration of exendin-9 during experimental hyperglycemia.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

実験的:Aim 2A sub-study [discont'd 8/2026]: Sequential glucose-stimulated insulin secretion

Aim 2A control sub-study [discontinued AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive an infusion of saline during both clamps and the procedure will align with the temporal pattern applied during all procedures in Aim 2A. Experiment: The experiment in this arm is the examination of potential time of day effects on glucose-stimulated insulin secretion.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Insulin secretion with and without exendin-9: Aims 2A and 2B
時間枠:4-8 weeks

Insulin secretion rates derived from deconvolution of C-peptide concentrations will be the primary outcome for insulin secretion. This measure will be compared within subjects in Aim 2A with the difference between the saline and exendin-9 clamps on each day used as the measure of fasting GLP-1 receptor mediated insulin secretion. Comparison of GLP-1 receptor mediated insulin secretion between the placebo and dexamethasone studies will be used to determine the effect of insulin resistance. Comparison of insulin secretion during the two sequential saline clamps in Aim 2A (revised 8/2026) and Aim 2A sub-study will be used to determine a time-of-day effect of subsequent glucose clamps.

Insulin secretion rates will also be compared within subjects in Aim 2B. Here the two different study days, one with saline and one with exendin-9 will be used.

4-8 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Insulin sensitivity: Aim 2B
時間枠:Insulin sensitivity will be measured in subjects participating in Aim 2B during the hyperinsulinemic clamp in each of the two days of study. The two experiments will be completed in a 4-6 week period.

Insulin sensitivity will be measured directly in subjects in Aim 2B during the hyperinsulinemic, euglycemic clamp. The glucose infusion rate necessary to maintain blood glucose at 6 mM divided by steady-state plasma insulin will be used as the index of insulin sensitivity.

Insulin sensitivity will be measured in subjects participating in Aim 2B during the hyperinsulinemic clamp in each of the two days of study. The two experiments will be completed in a 4-6 week period.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:David D'Alessio, MD、Duke University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月30日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2025年10月29日

QC基準を満たした最初の提出物

2025年11月2日

最初の投稿 (実際)

2025年11月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する